Correction: Stem Cells in the Treatment of Disease (New England Journal of Medicine (2019) 380 (1748-1760) DOI: 10.1056/NEJMra1716145);Stem cells in the treatment of disease

New England Journal of Medicine

Volumn 380, Issue 18, 2019, Pages 1748-1760

  Blau, Helen M ^a   Daley, George Q ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE RELATED MACULAR DEGENERATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD RETINA BARRIER; CELL SELF-RENEWAL; DUCHENNE MUSCULAR DYSTROPHY; EPIDERMOLYSIS BULLOSA; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; INSULIN DEPENDENT DIABETES MELLITUS; MUSCLE ATROPHY; NERVOUS TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RETINAL PIGMENT EPITHELIUM; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; VISUAL IMPAIRMENT; ANIMAL; CARDIOMYOPATHY; GENE THERAPY; MACULAR DEGENERATION; MULTIMODALITY CANCER THERAPY; STEM CELL; TRANSPLANTATION;

ANIMALS; CARDIOMYOPATHIES; COMBINED MODALITY THERAPY; EPIDERMOLYSIS BULLOSA; GENETIC THERAPY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MACULAR DEGENERATION; MUSCULAR DYSTROPHY, DUCHENNE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 85065132650     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx190025     Document Type: Erratum

References (87)

1. Blau HM, Pavlath GK, Hardeman EC, et al. Plasticity of the differentiated state. Science 1985;230:758-66.
2. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010;465:704-12.
3. Marion RM, Strati K, Li H, et al. Telo-meres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 2009;4:141-54.
4. Has C, Nyström A, Saeidian AH, Bruckner-Tuderman L, Uitto J. Epidermolysis bullosa: molecular pathology of connective tissue components in the cutaneous basement membrane zone. Matrix Biol 2018;71-72:313-29.
5. Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017;551:327-32.
6. Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA 2016;316:1808-17.
7. Wagner JE, Ishida-Yamamoto A, Mc-Grath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010;363:629-39.
8. Sebastiano V, Zhen HH, Haddad B, et al. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci Transl Med 2014;6:264ra163.
9. Fernández-Avilés F, Sanz-Ruiz R, Climent AM, et al. Global position paper on cardiovascular regenerative medicine. Eur Heart J 2017;38:2532-46.
10. Maliken BD, Molkentin JD. Undeniable evidence that the adult mammalian heart lacks an endogenous regenerative stem cell. Circulation 2018;138:806-8.
11. Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol 2016;1:831-41.
12. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
13. Porrello ER, Mahmoud AI, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart. Science 2011;331:1078-80.
14. Kang J, Hu J, Karra R, et al. Modulation of tissue repair by regeneration enhancer elements. Nature 2016;532:201-6.
15. Fernandes S, Chong JJH, Paige SL, et al. Comparison of human embryonic stem cell-derived cardiomyocytes, cardiovascular progenitors, and bone marrow mononuclear cells for cardiac repair. Stem Cell Reports 2015;5:753-62.
16. Kadota S, Pabon L, Reinecke H, Murry CE. In vivo maturation of human induced pluripotent stem cell-derived cardiomyocytes in neonatal and adult rat hearts. Stem Cell Reports 2017;8:278-89.
17. Chong JJ, Murry CE. Cardiac regeneration using pluripotent stem cells — progression to large animal models. Stem Cell Res 2014;13:654-65.
18. Zhu K, Wu Q, Ni C, et al. Lack of remuscularization following transplantation of human embryonic stem cell-derived cardiovascular progenitor cells in infarcted nonhuman primates. Circ Res 2018;122:958-69.
19. Menasché P, Vanneaux V, Hagège A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol 2018; 71:429-38.
20. Lee JH, Protze SI, Laksman Z, Backx PH, Keller GM. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct meso-derm populations. Cell Stem Cell 2017; 21(2):179-194.e4.
21. Stevens KR, Murry CE. Human pluripotent stem cell-derived engineered tissues: clinical considerations. Cell Stem Cell 2018;22:294-7.
22. Giacomelli E, Mummery CL, Bellin M. Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. Cell Mol Life Sci 2017;74:3711-39.
23. Chang ACY, Chang ACH, Kirillova A, et al. Telomere shortening is a hallmark of genetic cardiomyopathies. Proc Natl Acad Sci U S A 2018;115:9276-81.
24. Chen IY, Matsa E, Wu JC. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol 2016;13:333-49.
25. Stern JH, Tian Y, Funderburgh J, et al. Regenerating eye tissues to preserve and restore vision. Cell Stem Cell 2018;22: 834-49.
26. da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol 2018;36:328-37.
27. Davis RJ, Alam NM, Zhao C, et al. The developmental stage of adult human stem cell-derived retinal pigment epithelium cells influences transplant efficacy for vision rescue. Stem Cell Reports 2017;9: 42-9.
28. Song WK, Park KM, Kim HJ, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Reports 2015;4: 860-72.
29. Merkle FT, Ghosh S, Kamitaki N, et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 2017;545:229-33.
30. Mandai M, Wantanabe A, Kurimoto Y, et al. Autologous Induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med 2017;376:1038-46.
31. Garber K. Riken suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol 2015;33:890-1.
32. Hayashi R, Ishikawa Y, Sasamoto Y, et al. Co-ordinated ocular development from human iPS cells and recovery of corneal function. Nature 2016;531:376-80.
33. Rama P, Matuska S, Paganoni G, Spi-nelli A, De Luca M, Pellegrini G. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010;363:147-55.
34. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-28.
35. Gussoni E, Pavlath GK, Lanctot AM, et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 1992;356:435-8.
36. Alexander MS, Rozkalne A, Colletta A, et al. CD82 is a marker for prospective isolation of human muscle satellite cells and is linked to muscular dystrophies. Cell Stem Cell 2016;19:800-7.
37. Charville GW, Cheung TH, Yoo B, et al. Ex vivo expansion and in vivo self-renewal of human muscle stem cells. Stem Cell Reports 2015;5:621-32.
38. Garcia SM, Tamaki S, Lee S, et al. High-yield purification, preservation, and serial transplantation of human satellite cells. Stem Cell Reports 2018;10:1160-74.
39. Blau HM, Cosgrove BD, Ho AT. The central role of muscle stem cells in regenerative failure with aging. Nat Med 2015; 21:854-62.
40. Gilbert PM, Havenstrite KL, Magnus-son KE, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010;329:1078-81.
41. Ho ATV, Palla AR, Blake MR, et al. Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength. Proc Natl Acad Sci U S A 2017;114:6675-84.
42. Wang YX, Feige P, Brun CE, et al. EG-FR-Aurka signaling rescues polarity and regeneration defects in dystrophin-deficient muscle stem cells by increasing asymmetric divisions. Cell Stem Cell 2019;24(3):419-432.e6.
43. Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther 2017; 25:1125-31.
44. Amoasii L, Hildyard JCW, Li H, et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 2018;362:86-91.
45. Ho PP, Lahey LJ, Mourkioti F, et al. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. Proc Natl Acad Sci U S A 2018;115(39):E9182-E9191.
46. Pawlikowski B, Pulliam C, Betta ND, Kardon G, Olwin BB. Pervasive satellite cell contribution to uninjured adult muscle fibers. Skelet Muscle 2015;5:42.
47. Cossu G, Previtali SC, Napolitano S, et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol Med 2015;7:1513-28.
48. Darabi R, Arpke RW, Irion S, et al. Human ES- and iPS-derived myogenic progenitors restore dystrophin and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 2012; 10:610-9.
49. Chal J, Oginuma M, Al Tanoury Z, et al. Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy. Nat Biotechnol 2015; 33:962-9.
50. Hicks MR, Hiserodt J, Paras K, et al. ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 2018;20: 46-57.
51. Björklund A, Lindvall O. Replacing dopamine neurons in Parkinson’s disease: how did it happen? J Parkinsons Dis 2017;7:Suppl 1:S21-S31.
52. Li W, Englund E, Widner H, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating par-kinsonian brain. Proc Natl Acad Sci U S A 2016;113:6544-9.
53. Ganat YM, Calder EL, Kriks S, et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J Clin Invest 2012;122: 2928-39.
54. Kikuchi T, Morizane A, Doi D, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature 2017;548:592-6.
55. Steinbeck JA, Choi SJ, Mrejeru A, et al. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson’s disease model. Nat Biotechnol 2015;33:204-9.
56. Studer L. Strategies for bringing stem cell-derived dopamine neurons to the clinic — the NYSTEM trial. Prog Brain Res 2017;230:191-212.
57. Takahashi J. Strategies for bringing stem cell-derived dopamine neurons to the clinic: the Kyoto trial. Prog Brain Res 2017;230:213-26.
58. Barker RA, Parmar M, Studer L, Takahashi J. Human trials of stem cell-derived dopamine neurons for Parkinson’s disease: dawn of a new era. Cell Stem Cell 2017;21:569-73.
59. Assinck P, Duncan GJ, Hilton BJ, Ple-mel JR, Tetzlaff W. Cell transplantation therapy for spinal cord injury. Nat Neuro-sci 2017;20:637-47.
60. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004;429:41-6.
61. Kim Y, Kim H, Ko UH, et al. Islet-like organoids derived from human pluripotent stem cells efficiently function in the glucose responsiveness in vitro and in vivo. Sci Rep 2016;6:35145.
62. Pagliuca FW, Millman JR, Gürtler M, et al. Generation of functional human pancreatic β cells in vitro. Cell 2014;159: 428-39.
63. Rezania A, Bruin JE, Arora P, et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014; 32:1121-33.
64. Russ HA, Parent AV, Ringler JJ, et al. Controlled induction of human pancreatic progenitors produces functional beta-like cells in vitro. EMBO J 2015;34:1759-72.
65. Szot GL, Yadav M, Lang J, et al. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell 2015;16:148-57.
66. Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008;26:443-52.
67. Vegas AJ, Veiseh O, Gürtler M, et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med 2016;22:306-11.
68. Lu SJ, Feng Q, Park JS, et al. Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood 2008;112:4475-84.
69. Sugimura R, Jha DK, Han A, et al. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 2017;545:432-8.
70. Doulatov S, Vo LT, Chou SS, et al. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell 2013;13:459-70.
71. Moreau T, Evans AL, Vasquez L, et al. Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nat Commun 2016;7:11208.
72. Feng Q, Shabrani N, Thon JN, et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports 2014;3:817-31.
73. Nakamura S, Takayama N, Hirata S, et al. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell 2014; 14:535-48.
74. Ito Y, Nakamura S, Sugimoto N, et al. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production. Cell 2018;174(3):636-648.e18.
75. Thon JN, Mazutis L, Wu S, et al. Platelet bioreactor-on-a-chip. Blood 2014;124: 1857-67.
76. Majzner RG, Heitzeneder S, Mackall CL. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell 2017;31:476-85.
77. Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013;31:928-33.
78. Themeli M, Rivière I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 2015;16:357-66.
79. Sandler VM, Lis R, Liu Y, et al. Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature 2014;511:312-8.
80. Gori JL, Butler JM, Chan YY, et al. Vascular niche promotes hematopoietic mul-tipotent progenitor formation from pluripotent stem cells. J Clin Invest 2015;125: 1243-54.
81. Grandy R, Tomaz RA, Vallier L. Modeling disease with human inducible pluripotent stem cells. Annu Rev Pathol 2019; 14:449-68.
82. Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015;36:693-709.
83. Elitt MS, Barbar L, Tesar PJ. Drug screening for human genetic diseases using iPSC models. Hum Mol Genet 2018; 27:R2:R89-R98.
84. Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy 2016;8:1119-34.
85. D’Amour 0 KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006;24:1392-401.
86. Kobari L, Yates F, Oudrhiri N, et al. Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the eryth-ropoietic differentiation model. Haema-tologica 2012;97:1795-803.
87. Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol 2016;17:194-200.